Tesamorelin's safety record is better documented than most growth-hormone peptides, because one version has an FDA label. Egrifta, the brand, was tested in placebo-controlled trials, and its prescribing information lists what happened [1]. That record covers the brand only. Anything sold as "compounded tesamorelin" sits outside it, as the approval page explains.
The label lists known risks, and long-term heart safety is still open
Egrifta's label is specific about what is known and what is not. Its first section says long-term cardiovascular safety "has not been established" and tells prescribers to weigh continuing treatment in people whose belly fat did not fall [1].
The label reports 740 drug-treated adults across the clinical program. The initial randomized phase included 543 on tesamorelin and 263 on placebo [1]. Those pivotal efficacy trials involved adults with HIV-associated lipodystrophy; their results do not establish safety in other populations. The tesamorelin guide covers who it was studied in.
Joint pain and injection-site reactions are the most common side effects
The label names the reactions reported in more than 5% of people: arthralgia (joint pain), injection-site redness, injection-site itching, pain in the arms or legs, peripheral edema (swelling) and myalgia (muscle pain) [1]. Its trial table gives the rates against placebo.
| Risk | Egrifta | Placebo | Label section |
|---|---|---|---|
| Injection-site reactions (all types, first 26 weeks) | 25% | 14% | 5.6 |
| Injection-site reaction (table definition) | 17% | 6% | 6.1, Table 1 |
| Joint pain (arthralgia) | 13% | 11% | 6.1, Table 1 |
| Pain in arms or legs | 6% | 5% | 6.1, Table 1 |
| Muscle pain (myalgia) | 6% | 2% | 6.1, Table 1 |
| Swelling in the legs or feet (peripheral edema) | 6% | 2% | 6.1, Table 1 |
| Tingling (paresthesia) | 5% | 2% | 6.1, Table 1 |
| HbA1c reaching 6.5% or higher by week 26 | 5% | 1% | 5.4 |
| Hypersensitivity reactions (rash, hives, flushing, itching) | 4% of treated patients | Not given | 5.5 |
| Possible increased risk of neoplasms (tumors) | No rate given | No rate given | 5.1 |
| Fluid retention, including carpal tunnel syndrome | Carpal tunnel 1% | 0% | 5.3; Table 1 |
Trial rates are from the 26-week placebo-controlled phase (543 on Egrifta, 263 on placebo), as printed in the Egrifta SV label.
The label reports both injection-site figures in different sections. It does not explain the discrepancy, so the table preserves the section references rather than combining them. These are brand-trial figures, not rates for unapproved products.
Blood sugar rose into the diabetes range more often on the drug
Over 26 weeks, 5% of people on Egrifta reached an HbA1c of 6.5% or higher, against 1% on placebo. Section 6.1 reports a hazard ratio of 3.3 for developing diabetes against placebo (confidence interval 1.4 to 9.6) [1].
The trials themselves read more mildly. The first phase 3 trial reported no significant differences in glycemic measures at 26 weeks [3], and a pooled analysis of 806 patients found no clinically meaningful glucose changes at 26 or 52 weeks [4]. Theratechnologies sponsored both. Both readings are true at once: average glucose barely moved, while a small share of people crossed the diabetes line.
A separate trial in older adults points the same way. Among 66 people with mild cognitive impairment, 20 weeks of tesamorelin raised fasting insulin by 35%, though not in the healthy older adults in the same study [5]. That is why the label tells prescribers to evaluate glucose before starting and to monitor it during treatment.
The label rules it out with active cancer; it does not say tesamorelin causes cancer
Section 5.1 of the label is titled "Increased Risk of Neoplasms." Its reasoning is about mechanism, not a cancer count from the trials:
EGRIFTA SV induces the release of endogenous growth hormone (GH), a known growth factor. Do not treat patients with active malignancy with EGRIFTA SV.[1]
For people with a treated, stable cancer, the label says to start only after weighing the benefit against the risk of the cancer coming back, and to stop if it recurs. It also points to the higher background rate of cancer in people with HIV. The label describes a possible risk to weigh. It does not report that tesamorelin caused cancer in its trials.
A related point is IGF-1, a growth factor the drug raises. At 26 weeks, 47% of treated patients had IGF-1 more than 2 standard deviations above normal for age, and 36% more than 3. The label says the effects of prolonged high IGF-1 "are unknown" and tells prescribers to monitor it [1].
Fluid retention explains the swelling, joint pain and carpal tunnel
The label links several common reactions to one cause. Fluid retention "is thought to be related to the induction of GH secretion" and shows up as edema, joint pain and carpal tunnel syndrome, which "are either transient or resolve with discontinuation of treatment" [1]. If you notice swelling, numb fingers or new joint pain, tell your prescriber rather than waiting it out.
Two other warnings matter. Hypersensitivity reactions occurred in 4% of treated patients, and the label says to seek prompt medical attention if one is suspected. For people who are critically ill after major surgery or trauma, the label says to consider stopping, based on higher mortality reported with growth hormone in that setting.
Four groups should not use it at all
The label's contraindications are short [1]:
- People whose hypothalamic-pituitary axis is disrupted, for example after pituitary surgery, head radiation or head trauma.
- People with active cancer.
- People with known hypersensitivity to tesamorelin or the product's other ingredients.
- Pregnant women. The label says changing belly fat in pregnancy offers no benefit and could harm the fetus.
Two more cautions apply. The label says mothers taking Egrifta should not breastfeed, and the WR label says it is not indicated for children [2]. It also flags interactions: growth hormone can change how the liver clears some drugs, and people on glucocorticoid replacement may need a dose adjustment. Bring a full medication list to your prescriber.
Hunger, nausea and gas are not on the label's list
Increased hunger, nausea and gas do not appear in the label's table of reactions more common on the drug than on placebo. Two stomach items do: vomiting in 3% against 0% on placebo, and indigestion in 2% against 1% [1]. If a compounded product makes you feel sick, the label cannot tell you why, because that product was never part of the trials.
One more label finding surprises people. In the trials, anti-tesamorelin antibodies were found in 50% of patients after 26 weeks. People with and without antibodies had similar drops in belly fat, so the antibodies did not appear to cancel the effect [1].
Unapproved products cannot inherit the brand safety record
Every figure above comes from the brand. Since March 23, 2020, tesamorelin has been regulated as a biologic, and FDA's notice to compounders says such products are not eligible for the 503A and 503B compounding exemptions [6]. So no compounded version has passed through FDA's compounding framework, and none has an FDA-reviewed label.
| Question | Egrifta (brand) | "Compounded tesamorelin" |
|---|---|---|
| Side-effect rates from controlled trials? | Yes, on the label | No |
| FDA review of quality and sterility? | Yes, as a licensed biologic | No; no compounding exemption applies |
| Labeled contents and strength? | Specified in approved labeling | Not established by the brand label |
| FDA-approved contraindications and interactions? | Yes, sections 4 and 7 | No FDA-approved label |
| Long-term heart safety established? | No, per the label | No data |
Sources: Egrifta SV prescribing information (DailyMed, updated July 2026; prescribing information revised February 2024); FDA notice to compounders, March 2020.
The pharmacy question matters more here than for most drugs. A prescriber who names the brand and the dispensing pharmacy has given you something you can check. Our provider checks look for exactly that.
If a clinic suggests sermorelin as a substitute, its safety picture is different again: see is sermorelin safe and the tesamorelin vs sermorelin comparison. Whether the brand is worth those risks for your goal is the question in does tesamorelin work.